These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30590075)

  • 1. Immunoreactivity of a G protein-coupled l-DOPA receptor GPR143, in Lewy bodies.
    Goshima Y; Watanabe S; Seki E; Koga M; Masukawa D; Nakamura F; Komori T; Arai N
    Neurosci Res; 2019 Nov; 148():49-53. PubMed ID: 30590075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson's Disease.
    Goshima Y; Masukawa D; Kasahara Y; Hashimoto T; Aladeokin AC
    Front Pharmacol; 2019; 10():1119. PubMed ID: 31632270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coupling between GPR143 and dopamine D2 receptor is required for selective potentiation of dopamine D2 receptor function by L-3,4-dihydroxyphenylalanine in the dorsal striatum.
    Masukawa D; Kitamura S; Tajika R; Uchimura H; Arai M; Takada Y; Arisawa T; Otaki M; Kanai K; Kobayashi K; Miyazaki T; Goshima Y
    J Neurochem; 2023 Apr; 165(2):177-195. PubMed ID: 36807226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity.
    Irizarry MC; Growdon W; Gomez-Isla T; Newell K; George JM; Clayton DF; Hyman BT
    J Neuropathol Exp Neurol; 1998 Apr; 57(4):334-7. PubMed ID: 9600226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular actions of DOPA mediated by the gene product of ocular albinism 1.
    Goshima Y; Nakamura F; Masukawa D; Chen S; Koga M
    J Pharmacol Sci; 2014; 126(1):14-20. PubMed ID: 25185585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Lewy bodies in Parkinson's disease: histological, immunohistochemical, and interferometric examinations].
    Voronkov DN; Salkov VN; Anufriev PL; Khudoerkov RM
    Arkh Patol; 2018; 80(4):9-13. PubMed ID: 30059066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. l-3,4-Dihydroxyphenylalanine induces ptosis through a GPR143-independent mechanism in mice.
    Ueda S; Masukawa D; Koga M; Goshima Y
    J Pharmacol Sci; 2016 Sep; 132(1):109-112. PubMed ID: 27622543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TorsinA accumulation in Lewy bodies in sporadic Parkinson's disease.
    Shashidharan P; Good PF; Hsu A; Perl DP; Brin MF; Olanow CW
    Brain Res; 2000 Sep; 877(2):379-81. PubMed ID: 10986355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of the gene product of ocular albinism 1 (GPR143/OA1) but not its mutant forms inhibits neurite outgrowth in PC12 cells.
    Masukawa D; Yamada K; Goshima Y
    J Pharmacol Sci; 2019 Sep; 141(1):41-48. PubMed ID: 31606330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A deadly spread: cellular mechanisms of α-synuclein transfer.
    Steiner JA; Angot E; Brundin P
    Cell Death Differ; 2011 Sep; 18(9):1425-33. PubMed ID: 21566660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Localization of ocular albinism-1 gene product GPR143 in the rat central nervous system.
    Masukawa D; Nakamura F; Koga M; Kamiya M; Chen S; Yamashita N; Arai N; Goshima Y
    Neurosci Res; 2014 Nov; 88():49-57. PubMed ID: 25108060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of ocular albinism 1 (OA1), 3, 4- dihydroxy- L-phenylalanine (DOPA) receptor, in both neuronal and non-neuronal organs.
    Fukuda N; Naito S; Masukawa D; Kaneda M; Miyamoto H; Abe T; Yamashita Y; Endo I; Nakamura F; Goshima Y
    Brain Res; 2015 Mar; 1602():62-74. PubMed ID: 25601010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The mechanism of Lewy body formation in Parkinson's disease].
    Wakabayashi K; Takahashi H
    Nihon Rinsho; 2000 Oct; 58(10):2022-7. PubMed ID: 11068441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positive immunoreactivity for vesicular monoamine transporter 2 in Lewy bodies and Lewy neurites in substantia nigra.
    Yamamoto S; Fukae J; Mori H; Mizuno Y; Hattori N
    Neurosci Lett; 2006 Apr; 396(3):187-91. PubMed ID: 16386370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
    Hill WD; Arai M; Cohen JA; Trojanowski JQ
    J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory Mechanism of miR-543-3p on GLT-1 in a Mouse Model of Parkinson's Disease.
    Wu X; Meng X; Tan F; Jiao Z; Zhang X; Tong H; He X; Luo X; Xu P; Qu S
    ACS Chem Neurosci; 2019 Mar; 10(3):1791-1800. PubMed ID: 30676715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of Haloperidol-Induced Catalepsy by GPR143, an L-Dopa Receptor, in Striatal Cholinergic Interneurons.
    Arai M; Suzuki E; Kitamura S; Otaki M; Kanai K; Yamasaki M; Watanabe M; Kambe Y; Murata K; Takada Y; Arisawa T; Kobayashi K; Tajika R; Miyazaki T; Yamaguchi M; Lazarus M; Hayashi Y; Itohara S; de Kerchove d'Exaerde A; Nawa H; Kim R; Bito H; Momiyama T; Masukawa D; Goshima Y
    J Neurosci; 2024 Mar; 44(11):. PubMed ID: 38286627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Update on the pathophysiology of Parkinson' disease].
    Duyckaerts C; Sazdovitch V; Seilhean D
    Bull Acad Natl Med; 2010 Oct; 194(7):1287-303; discussion 1303-4. PubMed ID: 22043625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.